KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBT (2016 - 2025)

Historic EBT for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$12.4 million.

  • Neogenomics' EBT rose 2307.79% to -$12.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$110.3 million, marking a year-over-year decrease of 3668.17%. This contributed to the annual value of -$110.3 million for FY2025, which is 3668.17% down from last year.
  • As of Q4 2025, Neogenomics' EBT stood at -$12.4 million, which was up 2307.79% from -$26.4 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' EBT ranged from a high of $73.4 million in Q2 2021 and a low of -$53.2 million during Q1 2022
  • Its 5-year average for EBT is -$23.1 million, with a median of -$25.6 million in 2022.
  • Examining YoY changes over the last 5 years, Neogenomics' EBT showed a top increase of 50897.75% in 2021 and a maximum decrease of 114275.43% in 2021.
  • Quarter analysis of 5 years shows Neogenomics' EBT stood at -$44.2 million in 2021, then surged by 42.26% to -$25.5 million in 2022, then skyrocketed by 40.11% to -$15.3 million in 2023, then fell by 5.51% to -$16.1 million in 2024, then increased by 23.08% to -$12.4 million in 2025.
  • Its EBT stands at -$12.4 million for Q4 2025, versus -$26.4 million for Q3 2025 and -$45.8 million for Q2 2025.